RATIONALE: Exposure to ozone causes a decrease in spirometric lung function and an increase in airway inflammation in healthy young adults at concentrations as low as 0.08 ppm, close to the National Ambient Air Quality Standard for ground level ozone. OBJECTIVES: To test whether airway effects occur below the current ozone standard and if they are more pronounced in potentially susceptible individuals, such as those deficient in the antioxidant gene glutathione S-transferase mu 1 (GSTM1). METHODS: Pulmonary function and subjective symptoms were measured in 59 healthy young adults (19-35 yr) immediately before and after exposure to 0.0 (clean air, CA) and 0.06 ppm ozone for 6.6 hours in a chamber while undergoing intermittent moderate exercise. The polymorphonuclear neutrophil (PMN) influx was measured in 24 subjects 16 to 18 hours postexposure. MEASUREMENTS AND MAIN RESULTS: Subjects experienced a significantly greater (P = 0.008) change in FEV(1) (± SE) immediately after exposure to 0.06 ppm ozone compared with CA (-1.71 ± 0.50% vs. -0.002 ± 0.46%). The decrement in FVC was also greater (P = 0.02) after ozone versus CA (-2.32 ± 0.41% vs. -1.13 ± 0.34%). Similarly, changes in %PMN were greater after ozone (54.0 ± 4.6%) than CA (38.3 ± 3.7%) exposure (P < 0.001). Symptom scores were not different between ozone versus CA. There were no significant differences in changes in FEV(1), FVC, and %PMN between subjects with GSTM1-positive and GSTM1-null genotypes. CONCLUSIONS: Exposure of healthy young adults to 0.06 ppm ozone for 6.6 hours causes a significant decrement of FEV(1) and an increase in neutrophilic inflammation in the airways. GSTM1 genotype alone appears to have no significant role in modifying the effects.
RATIONALE: Exposure to ozone causes a decrease in spirometric lung function and an increase in airway inflammation in healthy young adults at concentrations as low as 0.08 ppm, close to the National Ambient Air Quality Standard for ground level ozone. OBJECTIVES: To test whether airway effects occur below the current ozone standard and if they are more pronounced in potentially susceptible individuals, such as those deficient in the antioxidant gene glutathione S-transferase mu 1 (GSTM1). METHODS: Pulmonary function and subjective symptoms were measured in 59 healthy young adults (19-35 yr) immediately before and after exposure to 0.0 (clean air, CA) and 0.06 ppm ozone for 6.6 hours in a chamber while undergoing intermittent moderate exercise. The polymorphonuclear neutrophil (PMN) influx was measured in 24 subjects 16 to 18 hours postexposure. MEASUREMENTS AND MAIN RESULTS: Subjects experienced a significantly greater (P = 0.008) change in FEV(1) (± SE) immediately after exposure to 0.06 ppm ozone compared with CA (-1.71 ± 0.50% vs. -0.002 ± 0.46%). The decrement in FVC was also greater (P = 0.02) after ozone versus CA (-2.32 ± 0.41% vs. -1.13 ± 0.34%). Similarly, changes in %PMN were greater after ozone (54.0 ± 4.6%) than CA (38.3 ± 3.7%) exposure (P < 0.001). Symptom scores were not different between ozone versus CA. There were no significant differences in changes in FEV(1), FVC, and %PMN between subjects with GSTM1-positive and GSTM1-null genotypes. CONCLUSIONS: Exposure of healthy young adults to 0.06 ppm ozone for 6.6 hours causes a significant decrement of FEV(1) and an increase in neutrophilic inflammation in the airways. GSTM1 genotype alone appears to have no significant role in modifying the effects.
Authors: Frank D Gilliland; Yu-Fen Li; Louis Dubeau; Kiros Berhane; Edward Avol; Rob McConnell; W James Gauderman; John M Peters Journal: Am J Respir Crit Care Med Date: 2002-08-15 Impact factor: 21.405
Authors: B Vagaggini; M Taccola; I Conti; S Carnevali; S Cianchetti; M L Bartoli; E Bacci; F L Dente; A Di Franco; D Giannini; P L Paggiaro Journal: Am J Respir Crit Care Med Date: 2001-12-15 Impact factor: 21.405
Authors: Edward S Schelegle; Christopher A Morales; William F Walby; Susan Marion; Roblee P Allen Journal: Am J Respir Crit Care Med Date: 2009-05-15 Impact factor: 21.405
Authors: Frank D Gilliland; W James Gauderman; Hita Vora; Edward Rappaport; Louis Dubeau Journal: Am J Respir Crit Care Med Date: 2002-09-01 Impact factor: 21.405
Authors: I Romieu; J J Sienra-Monge; M Ramírez-Aguilar; H Moreno-Macías; N I Reyes-Ruiz; B Estela del Río-Navarro; M Hernández-Avila; S J London Journal: Thorax Date: 2004-01 Impact factor: 9.139
Authors: Sarah Robertson; Elizabeth S Colombo; Selita N Lucas; Pamela R Hall; Maria Febbraio; Michael L Paffett; Matthew J Campen Journal: Toxicol Sci Date: 2013-05-06 Impact factor: 4.849
Authors: Benjamin Wells; Heather Simon; Thomas J Luben; Zachary Pekar; Scott M Jenkins Journal: Air Qual Atmos Health Date: 2019-03-07 Impact factor: 3.763
Authors: Carlos A Camargo; G R Scott Budinger; Gabriel J Escobar; Nadia N Hansel; Corrine K Hanson; Gary B Huffnagle; A Sonia Buist Journal: Ann Am Thorac Soc Date: 2014-04
Authors: Rebecca C Fry; Julia E Rager; Rebecca Bauer; Elizabeth Sebastian; David B Peden; Ilona Jaspers; Neil E Alexis Journal: Am J Physiol Lung Cell Mol Physiol Date: 2014-04-25 Impact factor: 5.464
Authors: Jae Hong Park; Imali A Mudunkotuwa; Jong Sung Kim; Aditya Stanam; Peter S Thorne; Vicki H Grassian; Thomas M Peters Journal: Aerosol Sci Technol Date: 2014-07-01 Impact factor: 2.908
Authors: Aimee Hoskins; Sara Reiss; Pingsheng Wu; Ning Chen; Wei Han; Rui-hong Do; Rasul Abdolrasulnia; Ryszard Dworski Journal: Am J Respir Crit Care Med Date: 2012-11-29 Impact factor: 21.405
Authors: Charles Barne; Neil E Alexis; Jonathan A Bernstein; John R Cohn; Jeffrey G Demain; Elliot Horner; Estelle Levetin; Andre Nei; Wanda Phipatanakul Journal: J Allergy Clin Immunol Pract Date: 2013-03